发明名称 |
Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
摘要 |
Disclosed are a number of substituted aryl acylthioureas and their pharmaceutically acceptable salts; wherein the specification lists the specific names of preferred compounds that are inhibitors of viral replication and are suitable for treating infectious diseases include viral infections, particularly HCV infections in human patients suffering from an infectious disease, and are also suitable for treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.
|
申请公布号 |
NZ551115(A) |
申请公布日期 |
2010.07.30 |
申请号 |
NZ20050551115 |
申请日期 |
2005.05.17 |
申请人 |
ACHILLION PHARMACEUTICALS, INC. |
发明人 |
PHADKE, AVINASH;CHEN, DAWEI;DESHPANDE, MILIND;THURKAUF, ANDREW;SHEN, YIPING;QUINN, JESSE;LI, SHOUMING;OHKANDA, JUNKO;WANG, XIANGZHU |
分类号 |
A61K31/17;C07D249/06;A61K31/277;A61K31/341;A61K31/343;A61K31/351;A61K31/352;A61K31/381;A61K31/415;A61K31/4155;A61K31/4164;A61K31/4192;A61K31/42;A61K31/421;A61K31/423;A61K31/4245;A61K31/426;A61K31/428;A61K31/429;A61K31/433;A61K31/4355;A61K31/437;A61K31/4375;A61K31/4406;A61K31/4412;A61K31/443;A61K31/445;A61K31/455;A61K31/47;A61K31/4725;A61K31/496;A61K31/498;A61K31/50;A61K31/505;A61K31/506;A61K31/519;A61K31/53;A61K31/5375;A61K31/5377;A61P31/12;C07C335/18;C07C335/20;C07C335/26;C07D211/20;C07D211/22;C07D211/46;C07D211/60;C07D211/64;C07D211/78;C07D213/56;C07D213/75;C07D213/82;C07D213/84;C07D213/85;C07D215/54;C07D231/14;C07D233/54;C07D233/60;C07D233/90;C07D237/24;C07D239/28;C07D241/24;C07D241/42;C07D241/44;C07D253/06;C07D253/07;C07D261/18;C07D263/34;C07D263/58;C07D265/30;C07D271/12;C07D277/20;C07D277/56;C07D277/68;C07D285/06;C07D295/10;C07D295/14;C07D295/15;C07D307/68;C07D307/84;C07D307/85;C07D309/38;C07D311/04;C07D311/58;C07D333/38;C07D401/04;C07D401/12;C07D405/04;C07D405/12;C07D405/14;C07D409/04;C07D409/12;C07D413/12;C07D417/04;C07D417/12;C07D417/14;C07D419/12;C07D471/04;C07D487/04;C07D491/04;C07D491/048;C07D495/04;C07D513/04 |
主分类号 |
A61K31/17 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|